FindTrial
Sign In

Outcomes After Treating Blockages in All Three Heart Arteries Using Stents in an Indian Hospital

TRIPLE VESSEL ANGIOPLASTY USING ULTRATHIN STRUT STENTS WITH BIODEGRADABLE POLYMER AND POLYMER FREE STENTS IN A TERTIARY CARE SETTING IN INDIA- A PROSPECTIVE OBSERVATIONAL STUDY - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/05/087025
Enrollment
46
Registered
2025-05-16
Start date
Unknown
Completion date
Unknown
Last updated
2025-05-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I210- ST elevation (STEMI) myocardial infarction of anterior wall Health Condition 2: I211- ST elevation (STEMI) myocardial infarction of inferior wall Health Condition 3: I212- ST elevation (STEMI) myocardial infarction of other sites Health Condition 4: I214- Non-ST elevation (NSTEMI) myocardial infarction

Interventions

Intervention1: Nil: Nil

Sponsors

AIIMS Bhubaneswar
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Patients diagnosed with triple vessel coronary artery disease, with and without LMCA involvement. 2.All lesions treated within the same hospital admission 3.Patients undergoing PCI with ultrathin strut stent with biodegradable polymer and polymer free stents. 4.Use of intravascular imaging for Left Main lesions. 5.Patient with high STS or EuroSCORE 2 scores 6.Patienst with low/intermediate SYNTAX score 7.Patient admitted with ACS or CCS 8.Written informed consent for study participation and follow-up.

Exclusion criteria

Exclusion criteria: 1.Patients with high SYNTAX score more than32 2.Intermediate to Low to Intermediate STS or EuroSCORE 2 3.Significantly reduced life expectancy due to non-cardiac comorbidities 4.Patients in cardiogenic shock or severe hemodynamic compromise precluding imaging-guided PCI. 5.Patients with prior CABG. 6.PCI performed for in-stent restenosis or stent thrombosis from a previous procedure 7.Known hypersensitivity to contrast agents, stent materials, or dual antiplatelet therapy 8.Patients unwilling to provide consent or adhere to follow-up protocols

Design outcomes

Primary

MeasureTime frame
Incidence of stent thrombosis and in-stent restenosis within 6 monthsTimepoint: Incidence of stent thrombosis and in-stent restenosis within 6 months—

Secondary

MeasureTime frame
3 point MACE at 6 Months which is Composite of CV death, non-fatal MI, non-fatal StrokeTimepoint: 6 months;Procedural Success which is TIMI grade 3Timepoint: 6 months;Complications such as Stent thrombosis, CIN, & vascular access site issuesTimepoint: 1 month,3 month,6 months—

Countries

India

Contacts

Public ContactMelvin Baby

AIIMS Bhubaneswar

cardio_ramachandra@aiimsbhubaneswar.edu.in9491634156

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026